Taken together, these findings provide evidence that CP can effectively ameliorate AD-like symptoms via the modulation of TSLP expression and NLRP3 inflammasome activation, impacting Th1/Th2 immune response (Figure 8). The gene discussed is TSLP; the disease is Alzheimer disease.